Moncayo-Arlandi Javier, Guasch Eduard, Sanz-de la Garza Maria, Casado Marta, Garcia Nahuel Aquiles, Mont Lluis, Sitges Marta, Knöll Ralph, Buyandelger Byambajav, Campuzano Oscar, Diez-Juan Antonio, Brugada Ramon
Cardiovascular Genetic Centre, Institute of Biomedical Research of Girona (IDIBGI), Girona, Spain.
Department of Biochemistry and Molecular Biology, University of Valencia, Valencia, Spain.
Hum Mol Genet. 2016 Sep 1;25(17):3676-3688. doi: 10.1093/hmg/ddw213. Epub 2016 Jul 12.
Arrhythmogenic cardiomyopathy (ACM) is a disorder characterized by a progressive ventricular myocardial replacement by fat and fibrosis, which lead to ventricular arrhythmias and sudden cardiac death. Mutations in the desmosomal gene Plakophilin-2 (PKP2) accounts for >40% of all known mutations, generally causing a truncated protein. In a PKP2-truncated mouse model, we hypothesize that content of transgene, endurance training and aging will be determinant in disease progression. In addition, we investigated the molecular defects associated with the phenotype in this model. We developed a transgenic mouse model containing a truncated PKP2 (PKP2-Ser329) and generated three transgenic lines expressing increasing transgene content. The pathophysiological features of ACM in this model were assessed. While we did not observe fibro-fatty replacement, ultrastructural defects were exhibited. Moreover, we observed transgene content-dependent development of structural (ventricle dilatation and dysfunction) and electrophysiological anomalies in mice (PR interval and QRS prolongation and arrhythmia induction). In concordance with pathological defects, we detected a content reduction and remodeling of the structural proteins Desmocollin-2, Plakoglobin, native Plakophilin-2, Desmin and β-Catenin as well as the electrical coupling proteins Connexin 43 and cardiac sodium channel (Na1.5). Surprisingly, we observed structural but not electrophysiological abnormalities only in trained and old mice. We demonstrated that truncated PKP2 provokes ACM in the absence of fibro-fatty replacement in the mouse. Transgene dose is essential to reveal the pathology, whereas aging and endurance training trigger limited phenotype. Molecular abnormalities underlay the structural and electrophysiological defects.
致心律失常性心肌病(ACM)是一种以脂肪和纤维化进行性替代心室心肌为特征的疾病,可导致室性心律失常和心源性猝死。桥粒蛋白-2(PKP2)基因的突变占所有已知突变的40%以上,通常会导致截短蛋白的产生。在一个PKP2截短的小鼠模型中,我们假设转基因含量、耐力训练和衰老将决定疾病的进展。此外,我们研究了该模型中与表型相关的分子缺陷。我们构建了一个包含截短型PKP2(PKP2-Ser329)的转基因小鼠模型,并产生了三个表达量逐渐增加的转基因品系。对该模型中ACM的病理生理特征进行了评估。虽然我们没有观察到纤维脂肪替代,但出现了超微结构缺陷。此外,我们观察到小鼠中结构(心室扩张和功能障碍)和电生理异常的发生与转基因含量有关(PR间期和QRS波增宽以及心律失常诱导)。与病理缺陷一致,我们检测到结构蛋白桥粒芯蛋白-2、桥粒斑珠蛋白、天然桥粒斑菲素蛋白-2、结蛋白和β-连环蛋白以及电耦联蛋白连接蛋白43和心脏钠通道(Na1.5)的含量减少和重塑。令人惊讶的是,我们仅在经过训练的老年小鼠中观察到结构异常,而非电生理异常。我们证明,在小鼠中,截短型PKP2在没有纤维脂肪替代的情况下也会引发ACM。转基因剂量对于揭示病理至关重要,而衰老和耐力训练只会引发有限的表型。分子异常是结构和电生理缺陷的基础。